Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
about
Modifiers and Readers of DNA Modifications and Their Impact on Genome Structure, Expression, and Stability in DiseaseMolecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted TherapyCytogenetic and molecular abnormalities in chronic myelomonocytic leukemiaIs lineage decision-making restricted during tumoral reprograming of haematopoietic stem cells?Epigenomics of cancer - emerging new conceptsMechanisms of epigenetic regulation of leukemia onset and progressionComprehensive genomic studies: emerging regulatory, strategic, and quality assurance challenges for biorepositoriesNew strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practiceThe de novo DNA methyltransferase DNMT3A in development and cancerThe role of DNA methylation in aging, rejuvenation, and age-related diseaseCIViC databaseSomatic SF3B1 mutation in myelodysplasia with ring sideroblastsDNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic DisordersEpigenetics in Cancer: A Hematological PerspectiveDefective control of pre-messenger RNA splicing in human diseaseOral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid LeukemiaStem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromesAge-related clonal hematopoiesis associated with adverse outcomesTen-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in miceLoss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesisEpigenetic Guardian: A Review of the DNA Methyltransferase DNMT3A in Acute Myeloid Leukaemia and Clonal Haematopoiesis.Established and emerging targeted therapies in the myelodysplastic syndromes.The mutational landscape of chromatin regulatory factors across 4,623 tumor samples.Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinibMyelodysplastic syndromes: Contemporary review and how we treat.Molecular Testing in Patients with Suspected Myelodysplastic Syndromes.Mutation analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese patients with myeloproliferative neoplasms.Novel impact of the DNMT3A R882H mutation on GSH metabolism in a K562 cell model established by TALENs.The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemiaThe challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failureEpigenetic therapies in MDS and AMLTumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome.The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.Dnmt3a is essential for hematopoietic stem cell differentiation.Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis.Clinical development of demethylating agents in hematologySomatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantationIdentification of pre-leukaemic haematopoietic stem cells in acute leukaemia.Epigenetic drugs against cancer: an evolving landscape.
P2860
Q26742136-9B1802F3-E699-4DC4-8380-2925B43134DEQ26749870-162AA45B-0B99-4B29-9792-E235738E27AFQ26768600-22A95341-2C0F-40E1-9C7D-6F19465B0E9DQ26779702-519C2BB5-5BA6-4C78-A701-6BC64119507DQ26830534-775CE900-41E2-48BB-9741-BB7D33C10F80Q26861785-8C5334C5-11F7-4D2F-B631-FCCDCA09BA57Q27009141-670C3E3A-3484-43CC-A187-D89A22760D67Q27016511-6809F29D-51A3-4F58-A69F-8DF4E87D69E0Q27021411-4985CE8C-CF2E-49D9-A5FF-98DC7CE64F87Q27025194-D648559D-3345-41C7-BF77-EA8ADB729488Q27612411-304867C0-8D80-44BE-AD75-38052AF63D98Q27851675-8CA03287-DA4F-4C7C-BBE1-B8F111E78634Q28073970-0AABCC4F-E983-420E-8BED-5F50D908AB4EQ28077082-AADBDEE8-37D4-4D1B-8758-F863B2A1FB0DQ28077564-1EA2D242-E3EC-4C13-A9B9-3F6241073BB8Q28084813-2CC13207-951D-439C-AB4F-CCED11085324Q28302909-C745D733-B291-4EED-A72C-5ED21BD6D413Q28386602-9FA24646-0BDD-4D18-AC7A-DD6D1BBF3BF8Q28511594-E3CE3BCC-2739-4DA7-BE9F-364B7E5DC4F7Q28589092-66688977-ED05-418B-86E1-B81ECD85FE2BQ30235316-C073EFE5-C753-4EB7-ABAD-CB92D2211E3FQ30245476-B869A217-55C1-4AA2-91E2-6389DF353059Q30580509-96354E2E-6AB5-4ED8-9A04-6215E83C000CQ33402522-6A0E2275-01FC-404F-9210-DBDAD700E946Q33429195-13FDA2BB-3DBC-4CC9-81FE-6370E06E8099Q33435980-2E838E42-1077-4E81-B7CB-83421FEE0111Q33667448-4FDC0B3B-9B84-4C87-B488-43C0017A0C39Q33728336-1541055A-A173-45DC-9B56-2A727A9F9C4FQ33796552-7F7F6319-68E5-453E-92AC-17E82F5F5C5CQ33829778-9A6A120D-18F1-4564-936D-99D3C1E382FCQ33863567-5ABC5DFF-CFB2-4248-8EFF-CDBBD12830DFQ33945004-EBEEC022-5AFA-4112-8F57-D2F7C5721C23Q34010735-55C9F7E9-89DC-46AD-A2C7-7C1FFD3CEAFFQ34069626-4F3E112B-95C8-497E-A3ED-FD18291872DBQ34237926-C2C25266-BF18-4048-8C3F-951CDD0691EBQ34384728-99D599D8-8675-471D-A622-A0EFC0AEC24FQ34395179-9A36F721-4AD7-42C5-89D0-30774038DBAEQ34396189-091296B9-D7A1-4768-8811-245F5EB7551BQ34403931-0FA4A512-895C-44B4-BE5B-0E93D3D4643CQ34431964-A35B44DA-65FB-409C-9B4A-CBA426097BC6
P2860
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
@ast
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
@en
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.
@nl
type
label
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
@ast
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
@en
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.
@nl
altLabel
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
@en
prefLabel
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
@ast
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
@en
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.
@nl
P2093
P2860
P921
P3181
P356
P1433
P1476
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
@en
P2093
E R Mardis
J F DiPersio
J Kalicki-Veizer
M J Walter
P2860
P2888
P304
P3181
P356
10.1038/LEU.2011.44
P577
2011-03-18T00:00:00Z
P5875
P6179
1023546509